Trial Profile

Efficacy and Mode of Action of Mesalazine in the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D).

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mesalazine (Primary)
Indications Irritable bowel syndrome
Focus Biomarker; Therapeutic Use
Acronyms MIBS

Most Recent Events

30 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
21 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
06 Jun 2013 Accrual to date is 125% according to United Kingdom Clinical Research Network record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com